Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC (BDRX) reported that 100 patients have enrolled in its registrational Phase 3 Serenta trial of eRapa for familial adenomatous polyposis (FAP). The trial is recruiting at 29 clinical sites across the U.S. and five European countries; two Canadian sites are expected to be initiated shortly.
The protocol calls for a pre-specified futility analysis after 25 progression-free-survival events and database lock after 75 events. Based on the current rate of event accrual, Chief Executive Officer Stephen Stamp said the analysis could take place early next year, with database lock potentially around the end of next year. Biodexa plans to enroll 168 subjects randomized 2:1, drug to placebo, and says the Phase 3 program is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas. The company states that FAP has no approved therapeutic option and that active surveillance and surgical resection remain the standard of care.
Biodexa Pharmaceuticals PLC (BDRX) supplements its resale prospectus for up to 10,950 ordinary shares, represented by 219 American Depositary Shares (ADSs).
The ADS ratio change is expected on or about October 26, 2026: each new ADS will represent 400 ordinary shares, compared with 50 under the prior ratio, and holders must surrender eight old ADSs for each new ADS. The ordinary shares are unaffected. No fractional ADSs will be allocated; aggregate fractions will be sold and net proceeds distributed to entitled holders. JPMorgan Chase Bank, N.A., the depositary, will contact ADS holders to arrange the exchange. ADSs last closed at $0.3832 on October 12, 2026.
Biodexa Pharmaceuticals PLC's prospectus supplement covers the resale by selling shareholders of up to 94,300 ordinary shares, represented by 1,886 ADSs. Separately, the company announced an ADS ratio change expected to take effect on or about October 26, 2026.
The ratio is changing from one ADS representing 50 ordinary shares to one ADS representing 400 ordinary shares. ADS holders will be required to surrender eight old ADSs for cancellation and exchange to receive one new ADS. No fractional ADSs will be allocated; aggregate fractions, if any, will be sold and net proceeds distributed to entitled ADS holders. The ordinary shares are unaffected.
Biodexa Pharmaceuticals Plc’s prospectus supplement covers the resale by a selling shareholder of up to 29,926,150 ordinary shares, represented by 598,523 American Depositary Shares (ADSs).
The ADS ratio is changing from one ADS for 50 ordinary shares to one ADS for 400 ordinary shares, with the change expected on or about October 26, 2026. ADS holders must surrender existing ADSs for cancellation and exchange eight old ADSs for one new ADS. No fractional ADSs will be allocated; any aggregate fractions will be sold and the net proceeds distributed to entitled holders. The ordinary shares are unaffected. ADSs closed at $0.3832 on October 12, 2026.
Biodexa Pharmaceuticals PLC’s Prospectus Supplement covers the resale by selling shareholders of up to 127,754,750 ordinary shares, represented by 2,555,095 ADSs. The shares are issuable upon exercise of pre-funded warrants and Series M, Series N and Series O warrants.
Biodexa announced an ADS ratio change expected on or about October 26, 2026: each new ADS will represent 400 ordinary shares, compared with 50 previously. ADS holders must surrender existing ADSs for cancellation and exchange, receiving one new ADS for every eight old ADSs; the ordinary shares are unaffected. No fractional ADSs will be allocated; aggregate fractions, if any, will be sold and net proceeds distributed to entitled ADS holders.
Biodexa Pharmaceuticals PLC (BDRX) supplements a resale registration for up to 17,150 ordinary shares, represented by 343 American Depositary Shares, for resale by the selling shareholders identified in the prospectus. The supplement incorporates the company’s October 8, 2026 report announcing an ADS ratio change.
The change is expected to take effect on or about October 26, 2026: each ADS will represent 400 ordinary shares instead of 50. ADS holders must surrender eight old ADSs for cancellation to receive one new ADS; the ordinary shares themselves are unaffected. No fractional ADSs will be allocated; any aggregate fractions will be sold and the net proceeds distributed to the entitled ADS holders.
Biodexa Pharmaceuticals Plc's prospectus supplement covers the resale by selling shareholders of up to 170,150 ordinary shares, represented by 3,403 American Depositary Shares (ADSs). An incorporated report announces a change from one ADS representing 50 ordinary shares to one ADS representing 400 ordinary shares, expected on or about October 26, 2026. ADS holders will be required to surrender eight old ADSs for one new ADS; the ordinary shares are unaffected.
Biodexa's ADSs closed at $0.3832 on October 12, 2026.
Biodexa Pharmaceuticals PLC’s prospectus covers issuance of up to 97,800 ADSs representing 4,890,000 ordinary shares upon exercise of pre-funded warrants, up to 1,219,512 ADSs representing 60,975,600 ordinary shares upon exercise of Series L warrants, and up to 30,487 ADSs representing 1,524,350 ordinary shares upon exercise of placement agent warrants. The best-efforts public offering was completed December 19, 2025, and ADSs underlying the pre-funded and Series L warrants are being offered on a continuous basis.
The ADS ratio is expected to change on or about October 26, 2026, from one ADS per 50 ordinary shares to one ADS per 400 ordinary shares. ADS holders will be required to surrender old ADSs for cancellation and exchange eight old ADSs for one new ADS; ordinary shares are unaffected. No fractional ADSs will be allocated; aggregated fractions will be sold and net proceeds distributed to entitled holders.
Biodexa Pharmaceuticals Plc’s prospectus supplement relates to the resale of up to 220,421,800 ordinary shares, represented by 4,408,436 American Depositary Shares (ADSs), issuable upon exercise of Series P warrants. It incorporates information about the ADS ratio change.
The ratio change is expected to take effect on or about October 26, 2026. ADS holders must surrender eight old ADSs for cancellation and exchange to receive one new ADS; no fractional ADSs will be allocated. Any aggregate fractions will be sold and the net proceeds distributed to entitled ADS holders. The ordinary shares are not affected.
Biodexa Pharmaceuticals Plc (BDRX) announced an American Depositary Share ratio change expected to take effect on or about October 26, 2026: one ADS will represent 400 ordinary shares, compared with one ADS representing 50 ordinary shares under the prior ratio.
ADS holders must surrender existing ADSs for cancellation and exchange to receive one new ADS for every eight old ADSs. No fractional ADSs will be allocated; any aggregate fractions will be sold, with net proceeds distributed to the entitled ADS holders. JPMorgan Chase Bank, N.A., the depositary, will contact holders and arrange the exchange. The ordinary shares themselves will not be affected.